Howe Jolanda 4

What Happened
Jolanda Howe, SVP & Global Controller of Mirum Pharmaceuticals (MIRM), was granted a total of 21,650 derivative awards on January 28, 2026: 7,680 units, 4,970 units and 9,000 units. Each award was reported at a $0.00 acquisition price (transaction code A — award/grant), meaning these are equity awards (restricted stock units and performance RSUs), not open‑market purchases or sales.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (filed within the standard two‑business‑day window).
• Reported grant amounts: 7,680 + 4,970 + 9,000 = 21,650 units. Reported price: $0.00 (award).
• Shares owned after the transaction: Not specified in the filing.
• Footnote highlights from the filing:
  • Some awards are time‑based RSUs with a 1‑year cliff (1/4 vests after 1 year) then monthly vesting over 36 months.
  • Each restricted stock unit represents the contingent right to one share.
  • Some RSUs vest 1/3 on each anniversary over three years.
  • A previously granted PSU award (granted Jan 23, 2024) had performance criteria achieved as of Jan 28, 2026; that PSU vests 2/3 on Mar 15, 2026 and 1/3 on Mar 15, 2027.
• Transaction code: A = Award/Grant (derivative awards), not a purchase (P) or sale (S).

Context
These grants are equity compensation subject to service and/or performance vesting schedules and represent future rights to receive common shares if vesting conditions are met. Because this is a grant (not a purchase or sale), it reflects compensation decisions by the company rather than a direct expression of the insider’s buying or selling intent. Some awards (PSUs) have performance conditions that were met and have scheduled vest dates in March 2026 and 2027.